1. Home
  2. FNGR vs TIL Comparison

FNGR vs TIL Comparison

Compare FNGR & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FingerMotion Inc.

FNGR

FingerMotion Inc.

HOLD

Current Price

$0.26

Market Cap

50.2M

Sector

Technology

ML Signal

HOLD

Logo Instil Bio Inc.

TIL

Instil Bio Inc.

N/A

Current Price

$7.20

Market Cap

48.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FNGR
TIL
Founded
2016
2018
Country
Singapore
United States
Employees
N/A
17
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.2M
48.4M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
FNGR
TIL
Price
$0.26
$7.20
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$125.00
AVG Volume (30 Days)
334.8K
11.3K
Earning Date
05-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.06
EPS
N/A
N/A
Revenue
$24,132,261.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$5.67
52 Week High
$2.35
$33.83

Technical Indicators

Market Signals
Indicator
FNGR
TIL
Relative Strength Index (RSI) 26.48 30.13
Support Level N/A $6.85
Resistance Level $0.45 $8.20
Average True Range (ATR) 0.04 0.23
MACD 0.00 -0.04
Stochastic Oscillator 2.48 13.04

Price Performance

Historical Comparison
FNGR
TIL

About FNGR FingerMotion Inc.

FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company's business line includes Telecommunications Products and Services, Value Added Products and Services, Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Share on Social Networks: